In this session, you will see the findings of our whitepaper Between Two Tests: why the interval between two lab tests is where engagement is lost, what the market has already done about it, and what sustained engagement is worth across three very different business models.
Understand why the gap between one test and the next is a structural problem rather than a marketing one, and why it shows up whether you sell tests directly, route screening through an insurer, or run a digital therapeutic.
See the public record of lab companies adding wearables and wearable companies adding lab tests, with the funding round or distribution deal behind each one, and what that convergence means if you are the one being evaluated against them.
Explore why the gold standards gain least from a continuous layer, which markers one tier below genuinely change when you add it, and how that plays out across three worked clinical cases in metabolic health, cardiovascular health and perimenopause.
See the cohort model run on real parameters, including where break-even sits, how far a typical cohort is from crossing it, and why we hand over the formula instead of a headline number.
Understand how the D2C diagnostics case transfers to models where acquisition cost is close to zero and the constraint becomes participation, adherence and reimbursement rather than payback.
This session is live, which means we will have live Q&A, so don’t be shy to bring questions. Can’t make it? Register anyway and we will send you the recording.